Tuberculosis (TB) is the leading cause of global morbidity and mortality caused by an infectious disease, with over 10 million new cases emerging in 2017. This global emergency is exacerbated by the emergence of multi-drug and extensively-drug resistant TB, therefore new drugs and new drug targets are urgently required. From a whole-cell phenotypic screen we identified a series of nitrogen-containing heterocyclic compounds that elicit potent anti-mycobacterial activity with MIC values <10 µM against Mycobacterium tuberculosis. Interestingly, this series of compounds demonstrate no detectable drug resistance in mycobacteria. Mode of action and target deconvolution studies suggest that these compounds inhibit mycobacterial growth by interfering with late-stage mycolic acid biosynthesis. In addition, these compounds exhibit a suitable toxicological and PK/PD profile that paves the way for further development as an anti-TB chemotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.